Tanaka M, Nakata K, Takase K, Mita S
Central Research Laboratories, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
Nihon Yakurigaku Zasshi. 1991 Apr;97(4):191-8. doi: 10.1254/fpj.97.4_191.
Effects of (4R)-hexahydro-7, 7-dimethyl-6-oxo-1, 2, 5-dithiazocine-4-carboxylic acid (SA3443) on acetaminophen-induced liver injury were investigated in BALB/c mice. SA3443 (30-300 mg/kg, p.o.) dose-dependently suppressed the elevation of serum transaminase activities and the histological changes of liver induced by acetaminophen (150 mg/kg, p.o.). The compound at the same doses also reduced the mortality due to the lethal acute hepatic failure induced by acetaminophen (350 mg/kg, p.o.). Other hepatoprotective agents, cianidanol (500 mg/kg, p.o.), malotilate (100 mg/kg, p.o.), grycyrrhizine (10 mg/kg, i.p.) and cysteine (300 mg/kg, p.o.) similarly reduced it. SA3443 had no effect on glutathione (GSH) contents in the liver of normal mice, but it dose-dependently suppressed the decrease of GSH contents in the liver of BALB/c mice treated with acetaminophen. These results suggest that SA3443, a novel cyclic disulfide, provides considerable protection against acetaminophen-induced liver injury and that one of the modes of the hepatoprotective action of this compound is suppression of the decrease of GSH contents in the liver.
在BALB/c小鼠中研究了(4R)-六氢-7,7-二甲基-6-氧代-1,2,5-二硫氮杂环辛烷-4-羧酸(SA3443)对乙酰氨基酚诱导的肝损伤的影响。SA3443(30 - 300毫克/千克,口服)剂量依赖性地抑制了乙酰氨基酚(150毫克/千克,口服)诱导的血清转氨酶活性升高和肝脏组织学变化。相同剂量的该化合物还降低了由乙酰氨基酚(350毫克/千克,口服)诱导的致死性急性肝衰竭所致的死亡率。其他肝保护剂,西尼地平(500毫克/千克,口服)、马洛替酯(100毫克/千克,口服)、甘草甜素(10毫克/千克,腹腔注射)和半胱氨酸(300毫克/千克,口服)也同样降低了死亡率。SA3443对正常小鼠肝脏中的谷胱甘肽(GSH)含量没有影响,但它剂量依赖性地抑制了用乙酰氨基酚处理的BALB/c小鼠肝脏中GSH含量的降低。这些结果表明,新型环状二硫化物SA3443对乙酰氨基酚诱导的肝损伤提供了相当大的保护作用,并且该化合物肝保护作用的模式之一是抑制肝脏中GSH含量的降低。